Top Pharma Companies Which Are Raking the Moolah in 2015 and Their Product Pipeline Market Research

Bangalore, India - July 15, 2015

The pharmaceutical industry is growing! A report by the World Health organization (WHO) indicates that the global pharmaceuticals market is currently worth US$300 billion a year. This figure is expected to rise to US$400 billion within the next three years. It also reports that the 10 largest pharmaceutical companies control over one-third of this market, several with sales of more than US$10 billion a year and profit margins of about 30%.

Another study indicates that Aging populations, chronic/lifestyle diseases, emerging-market expansion, and treatment and technology advances will drive growth in the pharmaceutical sector in 2015.

Having said this, we decided to put together the top pharmacetical companies that have created compelling product pipeline reports that will help you understand today's market, strategize better and make the right decisions!

Here are the product pipeline market research reports of some of the top pharmaceutical companies:

Actavis Plc

This Company specializes in manufacturing and commercializing of branded pharmaceuticals, generic and over-the-counter medicines, and biological products.

Actavis operates the world's third-largest generics business. The company is ranked in the top 3 in 12 global markets, top 5 in 16 global markets, and in the top 10 in 33 global markets. Recently, they acquired Allergan, Inc. (valued at approximately $70.5 billion). This merger has created one of the world's top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23 billion anticipated in 2015.

Click this link for Actavis pipeline and product research report.

Celgene

Valued at $90.4 Billion, this biotechnology company designs and manufactures therapies that treat cancer and immune-inflammatory related diseases. Its major products are Thalomid and Revlimid. Celgene works in collaboration with various pharmaceutical companies for the advancement of research in the field of cancer and inflammatory disorders.

Recently, they inked a collaboration deal with Astrazeneca (for $450 million) to study their Phase III immuno-oncology drug candidate. They also acquired Quanticel for $485 mn.

Click this link for Celgene pipeline and product research report

Amgen

This is the world's largest independent biotechnology firm. In past couple of years, Amgen's stock has been tripling in a four-year time span. The stimulus behind this success has been its late-stage pipeline. The company has announced that between 2014 and 2016, they are set to deliver 10 late-stage products; a few of these products have already displayed positive results and are now available on pharmacy shelves.

Amgen recently acquired oncology specialists Onyx and BioVex, elevating its market value, placing it beside market giants like Celgene.

Click this link for Amgen pipeline and product research report

Eli Lilly

The first company to mass-produce penicillin, the Salk polio vaccine, and insulin, now sells its products in over 125 countries. It is the world's largest manufacturer and distributor of psychiatric medications.

Among other collaborative relationships, the company recently announced its new $690 million deal to work with Hanmi Pharmaceutical in developing and commercializing Hanmi's Phase 1 Bruton's Tyrosine Kinase. It has also inked another $456 million deal with Innovent Biologics, Inc to co-develop and commercialise three of Innovent's treatments over the next decade.

Click this link for Eli Lilly pipeline and product research report

Gilead

A research-based biopharmaceutical company, it works to create innovative medicines in areas of unmet medical need. Forbes ranked them No 4 among the top 16 drug companies in 2013. They recently acquired Phenex Pharmaceuticals for $470 mn and EpiTherapeutics for $65mn.

Click this link for Gilead pipeline and product research report

AbbVie

This research-based biopharmaceutical company is expected to report an annual sales growth of 13.4% year-over-year—this is because of it's revenue-generating drugs such as Humira, Viekira Pak and the recently acquired Imbruvica

They have also signed collaborations to fight cancer (Infinity Pharmaceuticals for $805 mn), age-related diseases including neurodegeneration and cancer (Calico). They recently announced their global collaboration with Halozyme.

Click this link for AbbVie pipeline and product research report

Novartis

It was ranked No 1 in sales worldwide in 2013. Novartis' businesses are divided into six operating divisions: Pharmaceuticals, Alcon (eye care), Vaccines and Diagnostics, Sandoz (generics), Consumer (divided into two divisions: Over-the-Counter and Animal Health), and Corporate.

They recently launched a promising new heart-failure drug. Also, they've announced the acquisition of BipPharma ($ 85 mn) and Spinifex Pharmaceuticals ($ 200 mn).

Click this link for Novartis pipeline and product research report

Merck

Founded in 1891, Merck is the world's seventh largest pharmaceutical company by market capitalization and revenue. They recently had a successful launch of hepatitis C drug. After the booming success in the first quarter of this year, they have declared more profit in the next few quarters. They recently sold two of their experimental migraine drugs to Allergan PLC for $250 million.

Click this link for Merck pipeline and product research report

Astra Zeneca

Dated 2012, this company is the world's seventh-largest pharmaceutical company in terms of prescription drug sales. It has a market capitalization of £54.8 billion as on 2014.

They recently sold sells gastro drug for $215m to Swiss group Tillotts.

Click this link for AstraZeneca pipeline and product research report

Johnson & Johnson: This company has worldwide sales of $74.331 billion. In the pharmaceutical segment the company's major businesses are in the areas of Immunology, Neuroscience, Infectious Disease, and Oncology.

In 2014, the company announced that it is all set to acquire Alios BioPharma for $1.75 billion, adding it to their Janssen Pharmaceutical division.

Click this link for Johnson & Johnson pipeline and product research report

About Literated.com

Literated.com, is a market research portal, for accessing top pharmaceutical market research reports from reputed publishers as well as market research reports from across 10 industry verticals.

For more information about us, please visit https://literated.com

Contact Info:
Name: Sach
Email: info@literated.com
Phone: +91 8971520970